LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-16
Case ID: NM_000314.8_c.764_776delinsCAGAGTACCC_20261116_201424
Framework: ACMG/AMP 2015
Variant classification summary

NM_000314.8:c.764_776delinsCAGAGTACCC

PTEN  · NP_000305.3:p.(Val255_His259delinsAlaGluTyrPro)  · NM_000314.8
GRCh37: chr10:89717739 TAGAGTTCTTCCA>CAGAGTACCC  ·  GRCh38: chr10:87957982 TAGAGTTCTTCCA>CAGAGTACCC
Gene: PTEN Transcript: NM_000314.8
Final call
VUS
PM2 supporting
All criteria require review: For research and educational purposes only.
Gene
PTEN
Transcript
NM_000314.8
Protein
NP_000305.3:p.(Val255_His259delinsAlaGluTyrPro)
gnomAD AF
ClinVar
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
PM2 supporting: the variant is absent from gnomAD v2.1 and v4.1.
2
VUS: PM2 supporting alone does not satisfy a PTEN pathogenic or benign combination rule.
Final determination: Under the ClinGen PTEN Expert Panel Version 3.2 combining rules, PM2 at supporting strength alone does not satisfy any pathogenic or benign rule, so the classification is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: the exon 7 in-frame indel is outside the PTEN VCEP decision tree's covered null, splice-site, exon-deletion, duplication, and initiation-codon variant classes.
cspec vcep_pvs1_decisiontree_pten pvs1_variant_assessment
PS1 Not assessed Not assessed: no qualifying pathogenic comparator was identified for the complex p.(Val255_His259delinsAlaGluTyrPro) change.
cspec pm5_candidates
PS2 Not assessed Not assessed: no proband disease status, family-history information, or confirmed maternity and paternity is documented for the required de novo observation.
cspec
PS3 Not assessed Not assessed: mmc2.xlsx contains no exact row for the in-frame delins, so no VCEP-qualified phosphatase activity or high-confidence cumulative score is available.
cspec vcep_mmc2 PMID:29706350
PS4 Not assessed Not assessed: no affected/control counts, odds ratio, confidence interval, or PTEN phenotype-specific proband scores are available to evaluate PS4.
cspec
PM1 Not met Not met: residues 255-259 lie outside all VCEP-approved catalytic motifs 90-94, 123-130, and 166-168, with no reported hotspot.
cspec hotspots
PM2 Met Met at supporting strength: the variant is absent from gnomAD v2.1 and v4.1, satisfying the VCEP's <0.00001 (0.001%) population-frequency requirement.
cspec gnomad_v2 gnomad_v4
PM3 N/A Not applicable: the PTEN VCEP Version 3.2 CSPEC explicitly designates PM3 as not applicable.
cspec
PM4 Not met Not met: residues 255-259 are altered, but the PTEN VCEP PM4 gate requires an in-frame indel to affect catalytic motifs 90-94, 123-130, or 166-168.
cspec pvs1_variant_assessment
PM5 N/A Not applicable: the variant is an in-frame indel spanning residues 255-259, whereas the VCEP PM5 rule requires a missense change.
cspec pm5_candidates
PM6 Not assessed Not assessed: no assumed de novo observation, proband disease status, or no-family-history documentation is available for PM6 evaluation.
cspec
PP1 Not assessed Not assessed: zero affected-family-member segregation observations and zero documented meioses are available to compare with the VCEP thresholds.
cspec
PP2 N/A Not applicable: PP2 requires a missense variant, but this variant is an in-frame indel affecting residues 255-259.
cspec
PP3 N/A Not applicable: this is an in-frame indel, whereas PTEN PP3 names only splicing concordance or missense REVEL > 0.7.
cspec
PP4 N/A Not applicable: the PTEN VCEP incorporates phenotype specificity into PS4 Use 2 rather than allowing independent PP4 application.
cspec
PP5 N/A Not applicable: the PTEN VCEP explicitly prohibits use of PP5 under its specification.
cspec
BA1 Not met Not met: the variant is absent from gnomAD v2.1 and v4.1, rather than exceeding the VCEP's 0.00056 (0.056%) threshold.
cspec gnomad_v2 gnomad_v4
BS1 Not met Not met: no gnomAD allele frequency is observed, whereas BS1 Strong requires 0.000043-0.00056 (0.0043%-0.056%).
cspec gnomad_v2 gnomad_v4
BS2 Not assessed Not assessed: gnomAD reports absence and provides no homozygous observation or parental-confirmation data required by the VCEP.
cspec gnomad_v2 gnomad_v4
BS3 Not assessed Not assessed: mmc2.xlsx contains no exact row for the in-frame delins, so no VCEP-qualified phosphatase activity above zero or high-confidence benign assay result is available.
cspec vcep_mmc2 PMID:29706350
BS4 Not assessed Not assessed: no affected family member with genotype and phenotype data is documented, so lack of segregation in one or more families cannot be determined.
cspec
BP1 N/A Not applicable: the PTEN VCEP explicitly marks BP1 as not applicable.
cspec
BP2 Not assessed Not assessed: zero affected-proband or cis/trans observations with a different pathogenic or likely pathogenic PTEN variant are available.
cspec clinvar
BP3 N/A Not applicable: the PTEN VCEP explicitly states that BP3 is not applicable to PTEN.
cspec
BP4 N/A Not applicable: this is an in-frame indel, whereas PTEN BP4 names only splicing concordance or missense REVEL < 0.5.
cspec
BP5 Not assessed Not assessed: no two cases with an alternate highly penetrant molecular diagnosis and non-overlapping PTEN histories are documented.
cspec
BP6 N/A Not applicable: the PTEN VCEP explicitly prohibits use of BP6 under its specification.
cspec
BP7 N/A Not applicable: BP7 covers synonymous or intronic variants at or beyond +7/-21, not this exonic in-frame indel.
cspec
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.